Investigational drug · Phase 3
SHR6508
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Secondary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis.
Phase 3Last checked: Nov 19, 2026Latest source record: May 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "SHR6508"
First trial start
2024
Feb 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR6508", any sponsor or status.
Conditions studied
As listed on its trial records.
- Secondary Hyperparathyroidism
- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR6508" as an intervention, largest first.
- The Trial of SHR6508 in Secondary HyperparathyroidismPivotal-lookingCompleted
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06434961 · 498 participants · Start Jun 14, 2024 · Primary completion Sep 29, 2025
Drug: SHR6508 plus oral placebo tablets; Cinacalcet plus intravenous placebo · For: Secondary Hyperparathyroidism
Sites: Guangzhou, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06236295 · 303 participants · Start Feb 20, 2024 · Primary completion Nov 13, 2025
Drug: SHR6508 · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Beijing, China
- A Study of SHR6508 in Secondary HyperparathyroidismStatus unknown
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05663411 · 75 participants · Start Feb 24, 2023 · Primary completion Oct 31, 2023
Drug: SHR6508; SHR6508 and 1 more · For: Secondary Hyperparathyroidism
Sites: Guangzhou, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05221008 · 54 participants · Start Mar 10, 2022 · Primary completion Jul 7, 2023
Drug: SHR6508;Placebo; SHR6508;Placebo and 2 more · For: Secondary Hyperparathyroidism
Sites: Guangzhou, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06877247 · 5 participants · Start Dec 23, 2024 · Primary completion Apr 4, 2025
Drug: [14C] SHR6508 Injection · For: Secondary Hyperparathyroidism
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Overcoming Stability Challenge During the Quantification of SHR6508 in Human Plasma by LC-MS/MS.
Wu Y, Chen T, Zhong K, et al. · Biomed Chromatogr 2026
- Safety, Pharmacokinetics, and Pharmacodynamics of SHR6508, a Calcium-Sensing Receptor Agonist, in Maintenance Hemodialysis Patients With Secondary Hyperparathyroidism: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Li S, Fan L, Yan R, et al. · Kidney Med 2026
- The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial.
Zhang ST, Tan HY, Yang S, et al. · Naunyn Schmiedebergs Arch Pharmacol 2025
- Corrigendum to "WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM" [Kidney International Reports Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369].
Ye Z, Fan L, Yan R, et al. · Kidney Int Rep 2024
Also in development for Secondary Hyperparathyroidism
- PLS240upacicalcetPhase 33 trials
Pathalys Pharma · Secondary Hyperparathyroidism, Chronic Kidney Disease (CKD), End-stage Kidney Disease (ESKD)
- Open-Label Extension PLS240Phase 32 trials
Pathalys Pharma · Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD), End Stage Kidney Disease
- CTAP101Phase 21 trial
OPKO Health, Inc. · CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.